Press releaseGlobe Newswire
InterCure
INCR · TEL
$4.43−$0.03 (−0.67%)TodayMarket closed ·
Prev close $4.46
Latest news
- Press releaseGlobe Newswire
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
- Press releaseGlobe Newswire
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
- Press releaseGlobe Newswire
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
- News
InterCure Ltd. Receives Nasdaq Non-Compliance Notice, Granted Until August 24, 2026 To Regain Compliance
- Press releaseGlobe Newswire
InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement
- Press releaseGlobe Newswire
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million
- Press releaseGlobe Newswire
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million
- NewsVishaal Sanjay
Trump's Marijuana Reclassification Looks Set To Send This Cannabis ETF Soaring: Big Surge In Momentum
- News
InterCure Enters Into Definitive Share Purchase Agreement And Collaboration Agreement With Cannasoul To Advance Cannabis Science And Pharmaceutical Innovation
- Press releaseGlobe Newswire
InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
- News
Intercure H1 EPS $0.01 Up From $0.00 YoY, Sales $36.292M Miss $66.530M Estimate
- Press releaseGlobe Newswire
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
- NewsNabaparna Bhattacharya
InterCure Enters Premium US Cannabis Market With ISHI Deal
- Press releaseGlobe Newswire
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
- Press releasePRNewswire
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025
- Press releasePRNewswire
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak
- Press releasePRNewswire
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility
- NewsNicolás Jose Rodriguez
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company
- NewsNina Zdinjak
Top Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On Germany
- Press releaseGlobe Newswire
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million
- Press releaseBusiness Wire
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.